Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GPR132 | Q9UNW8 | 4/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080257 | 0.85 | PTGS2 (0.38) | GRM2LMNAHPGDHTTSMN1; SMN2 | |
| SCHEMBL7077441 | 0.82 | AGTR1 (0.33) | TDP1CYP3A4 | |
| SCHEMBL7076731 | 0.73 | RAPGEF3 (0.43) | SMN1; SMN2ALDH1A1KMT2ATDP1 | |
| SCHEMBL7080331 | 0.71 | SGMS2 (0.52) | KMT2A | |
| SCHEMBL7080256 | 0.64 | HSD17B10 (0.50) | HPGDHTTALDH1A1NAMPTKMT2A | |
| SCHEMBL10175270 | 0.62 | FAAH (0.51) | LMNAHTTALDH1A1NAMPTKMT2A | |
| SCHEMBL2433131 | 0.62 | MAPT (0.75) | LMNAHPGDHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL7083951 | 0.62 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL29165186 | 0.62 | CA9 (0.55) | ALDH1A1KMT2A | |
| SCHEMBL2810873 | 0.62 | EPHX2 (0.55) | HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162818-A1 | Acylsulfonamide derivative | AJINOMOTO CO. INC. (JP) | 2003-08-28 | — | — | US | disclosed |
| US-6555584-B1 | Acetyl-coa carboxylase inhibitors | AJINOMOTO CO., INC. (JP) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162818-A1 | Acylsulfonamide derivative | ACSS2, ACACA, FASN | GRM2 3332/4885LMNA 2629/4885HPGD 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.